Literature DB >> 18481816

Assessing the current role of platelet function testing.

Eugene Braunwald1, Dominick Angiolillo, Eric Bates, Peter B Berger, Deepak Bhatt, Christopher P Cannon, Mark I Furman, Paul Gurbel, Alan D Michelson, Eric Peterson, Stephen Wiviott.   

Abstract

In vitro platelet function tests are commonly applied in research and offer justification for using antiplatelet therapy. However, studies assessing the ability of standardized platelet function tests to predict patients' clinical response to aspirin or clopidogrel have generated contradictory results. At this time, there is no standardized definition for resistance to antiplatelet therapy, and the appropriate treatment of patients who are hyporesponsive to these agents is not known. Although such tests have a role in research, their place in guiding therapy remains to be established, and prospective trials are urgently needed. The ideal platelet function test for clinical practice would be rapid, easy-to-use, inexpensive, and reliable. Copyright (c) 2008 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18481816      PMCID: PMC6653601          DOI: 10.1002/clc.20361

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  22 in total

Review 1.  Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology.

Authors:  Carlo Patrono; Fedor Bachmann; Colin Baigent; Christopher Bode; Raffaele De Caterina; Bernard Charbonnier; Desmond Fitzgerald; Jack Hirsh; Steen Husted; Jan Kvasnicka; Gilles Montalescot; Luis Alberto García Rodríguez; Freek Verheugt; Jozef Vermylen; Lars Wallentin; Silvia G Priori; Maria Angeles Alonso Garcia; Jean Jacques Blanc; Andrzej Budaj; Martin Cowie; Veronica Dean; Jaap Deckers; Enrique Fernández Burgos; John Lekakis; Bertil Lindahl; Gianfranco Mazzotta; João Morais; Ali Oto; Otto A Smiseth; João Morais; Jaap Deckers; Rafael Ferreira; Gianfranco Mazzotta; Philippe Gabriel Steg; Frederico Teixeira; Robert Wilcox
Journal:  Eur Heart J       Date:  2004-01       Impact factor: 29.983

2.  Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation.

Authors:  Paul Barragan; Jean-Louis Bouvier; Pierre-Olivier Roquebert; Gilles Macaluso; Philippe Commeau; Bertrand Comet; Antoine Lafont; Laurence Camoin; Ulrich Walter; Martin Eigenthaler
Journal:  Catheter Cardiovasc Interv       Date:  2003-07       Impact factor: 2.692

Review 3.  Platelet function testing in cardiovascular diseases.

Authors:  Alan D Michelson
Journal:  Circulation       Date:  2004-11-09       Impact factor: 29.690

4.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

Authors:  Eugène P McFadden; Eugenio Stabile; Evelyn Regar; Edouard Cheneau; Andrew T L Ong; Timothy Kinnaird; William O Suddath; Neil J Weissman; Rebecca Torguson; Kenneth M Kent; August D Pichard; Lowell F Satler; Ron Waksman; Patrick W Serruys
Journal:  Lancet       Date:  2004 Oct 23-29       Impact factor: 79.321

5.  Profile and prevalence of aspirin resistance in patients with cardiovascular disease.

Authors:  P A Gum; K Kottke-Marchant; E D Poggio; H Gurm; P A Welsh; L Brooks; S K Sapp; E J Topol
Journal:  Am J Cardiol       Date:  2001-08-01       Impact factor: 2.778

6.  Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events.

Authors:  John W Eikelboom; Jack Hirsh; Jeffrey I Weitz; Marilyn Johnston; Qilong Yi; Salim Yusuf
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

7.  Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

Authors:  Ioannis Iakovou; Thomas Schmidt; Erminio Bonizzoni; Lei Ge; Giuseppe M Sangiorgi; Goran Stankovic; Flavio Airoldi; Alaide Chieffo; Matteo Montorfano; Mauro Carlino; Iassen Michev; Nicola Corvaja; Carlo Briguori; Ulrich Gerckens; Eberhard Grube; Antonio Colombo
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

8.  Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction.

Authors:  Shlomi Matetzky; Boris Shenkman; Victor Guetta; Michael Shechter; Roy Beinart; Roy Bienart; Ilan Goldenberg; Ilya Novikov; Hanna Pres; Naphtali Savion; David Varon; Hanoch Hod
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

9.  Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment.

Authors:  Wai-Hong Chen; Pui-Yin Lee; William Ng; Hung-Fat Tse; Chu-Pak Lau
Journal:  J Am Coll Cardiol       Date:  2004-03-17       Impact factor: 24.094

10.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease.

Authors:  Patricia A Gum; Kandice Kottke-Marchant; Patricia A Welsh; Jennifer White; Eric J Topol
Journal:  J Am Coll Cardiol       Date:  2003-03-19       Impact factor: 24.094

View more
  8 in total

Review 1.  New antithrombotic drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Jeffrey I Weitz; John W Eikelboom; Meyer Michel Samama
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

2.  Aspirin resistance in hemodialysis patients.

Authors:  Abdallah Sassine Geara; Nassif Azzi; Claude Bassil; Suzanne El-Sayegh
Journal:  Int Urol Nephrol       Date:  2010-07-25       Impact factor: 2.370

3.  State of the art in platelet function testing.

Authors:  Beate E Kehrel; Martin F Brodde
Journal:  Transfus Med Hemother       Date:  2013-03-18       Impact factor: 3.747

4.  Clinical importance of aspirin and clopidogrel resistance.

Authors:  Gergely Feher; Andrea Feher; Gabriella Pusch; Katalin Koltai; Antal Tibold; Beata Gasztonyi; Elod Papp; Laszlo Szapary; Gabor Kesmarky; Kalman Toth
Journal:  World J Cardiol       Date:  2010-07-26

5.  Clopidogrel Resistance by P2Y12 Platelet Function Testing in Patients Undergoing Neuroendovascular Procedures: Incidence of Ischemic and Hemorrhagic Complications.

Authors:  Jerah D Nordeen; Alden V Patel; Robert M Darracott; Gretchen S Johns; Philipp Taussky; Rabih G Tawk; David A Miller; William D Freeman; Ricardo A Hanel
Journal:  J Vasc Interv Neurol       Date:  2013-06

6.  Comparative efficacy of in vitro and in vivo metabolized aspirin in the DeBakey ventricular assist device.

Authors:  Jawaad Sheriff; Gaurav Girdhar; Wei-Che Chiu; Jolyon Jesty; Marvin J Slepian; Danny Bluestein
Journal:  J Thromb Thrombolysis       Date:  2014-05       Impact factor: 2.300

7.  Resistance to Clopidogrel among Iranian Patients Undergoing Angioplasty Intervention.

Authors:  Mohammad Haji Aghajani; Farzad Kobarfard; Olia Safi; Kourosh Sheibani; Mohammad Sistanizad
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

Review 8.  Platelet Aggregometry Testing: Molecular Mechanisms, Techniques and Clinical Implications.

Authors:  Katalin Koltai; Gabor Kesmarky; Gergely Feher; Antal Tibold; Kalman Toth
Journal:  Int J Mol Sci       Date:  2017-08-18       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.